- Global Pharma News & Resources

At 6.10% CAGR, Multiple Sclerosis Drugs Market Size to Surpass USD 36251.02 Million by 2025

Pune, Maharashtra, India, August 28 2020 (Wiredrelease) Brandessence Market Research and Consulting Pvt ltd –: The latest research report on Multiple Sclerosis Drugs Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrate its growth trends and competitive landscape as well as the key players in the business.

Multiple Sclerosis Market Size

Multiple Sclerosis Drugs Market is valued at USD 23950.39Million in 2018 and expected to reach USD 36251.02 Million by 2025 with the CAGR of 6.10% over the forecast period.

Get Sample of This Report@

Multiple sclerosis (MS) is a nervous system disease which affects & disrupts communication between spinal cord and the brain. MS damages the myelin sheath which is insulating layer of the nervous system of the body. Myelin sheath is a surrounds and protects human nerve cells. This damage blocks messages between brain and the body and leads to the symptoms of MS. Some of the major symptoms of MS include thinking and memory problems, vision loss, pain, fatigue and impaired coordination, problem in coordination & balancing of the body and muscle weakness. These symptoms vary from person to person and mostly the chances of MS are higher in women than in men which occur in the age group of 20 to 40. Physiotherapy and certain type of drug medications help in suppressing the immune system and slower disease progression. The most common drugs used for the treatment of MS are Avonex, Betaseron, Copaxone, Extavia, Glatiramer Acetate Injection, Aubagio , Gilenya, Mavenclad, Mayzent whereas in infused drugs include Lemtrada Novantrone, Ocrevus and many others. There are certain forms of MS diseases i.e. elapse-remitting and primary-progressive which can be cured by using anti-inflammatory, immunosuppressive drugs and steroids.

The global multiple sclerosis drugs services market is segmented on the basis of drug class, route of administration, distribution channel and region. Based on drug class the global multiple sclerosis drugs market is segmented into immune modulator, immune suppressant, interferon, others. Based on route of administration the multiple sclerosis drugs market is segmented by oral, injection, intravenous, infused and others. Based on distribution channel the multiple sclerosis drugs market is segmented by hospital pharmacy, retail pharmacy, and online stores.

The regions covered in global multiple sclerosis drugs marketreport are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Top Key players for Multiple Sclerosis Drugs

Global multiple sclerosis drugs market reports cover prominent players F. Hoffmann-La, Novartis AG, Roche Ltd, Biogen, Sanofi, Bayer, GlaxoSmithKline, Teva Pharmaceutical, Merck, Serono, Pfizer, Abbvie, Biogen Idec, AB Science and Opexa and many others.

Multiple Sclerosis News

German Merck has received approval for MS drug Mavenclad

News: 2 April 2019, The Food and Drug Administration (FDA) has been approved Merck KGaA’sMavenclad for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Mavenclad drug is provided through oral and used for 10 days a year. In spite of small administration time, the drug’s level is restrictive due to safety purpose. Mavenclad can only be used for two years and not repeated due its potential market is relatively small.In approving Mavenclad, the FDA has been recommended that the drug only be used for patients who have unable to tolerateor an inadequate response then another drug OK’d used for multiple sclerosis.

Global Multiple Sclerosis Drugs Services Market Dynamics –

 The key factor for growth of global multiple sclerosis drugs market is the rise of demand in the market by pharmaceutical and biotechnological companies with surge in research and development activities including various clinical trials for advanced new drugs against MS disease with huge investment.Recently Biogen the major pharmaceutical drugs manufacturing company had bought a brain disorder drug helpful to treat neurological and inflammatory conditions including MS for USD 217 million. In addition to this, according to the report of Pharmaceutical Research and Manufacturers of America in 2009, America’s pharmaceutical research and biotechnology companies holds huge investment in pharmaceutical R&D with USD 65.3 billion spent on R&D, including USD 45.8 billion by PhRMA members alone and has been risen up to USD 1.1 trillion with rising number of clinical trials with producing new 7000 drugs by the year 2019. However, global multiple sclerosis drugs market can be hampered by the high investment require to manufacture new drugs, patent expiry as well as strict government rule and regulations. Moreover rising focus on biological medicines with technological advancement using artificial intelligence, nano-technology for the clinical drugs manufacturingmay form the huge opportunity to fuel the global multiple sclerosis drugs market during the forecast period as specialty medicines require scientific expertise and researchers.

Multiple Sclerosis Market Regional Analysis –

North America is dominating the multiple sclerosis drugs market with the potential rate due to presence of biopharmaceutical, and pharmaceutical companies for clinical research studies.According to the Pharmaceutical Research and Manufacturers Association (PhRMA), U.S. firms has more than half of the world’s Research &Development  in pharmaceuticals spending USD 75 billion and hold the intellectual property rights on most new medicines through its advanced contract based clinical research. The U.S. has the substantial overall economic impact of the biopharmaceutical industry which accounted for more than USD 1.3 trillion in economic output, representing 4 percent of total U.S. output in 2015 alone. Thisbiopharmaceutical businesses economic impact has revenue generated in 2015 was USD 558 billion.

Europe is the second-largest region for dominating the growth of multiple sclerosis drugs due to rise  cases of diseases likemultiple sclerosis, cardiovascular diseases, cancer etc. as well as surge in investment in R&D for treatment of this diseases in this region. According to European Federation of Pharmaceutical Industries and Associations in 2017, the Europe had invested an around Euro 35,200 million in Research &Development.

The Asia Pacific is expected to emerge as the fastest-growing regional market due to rapidly increasing manufacturing companies, availability of labor at lower cost as well as rising population in this region. The growth for the multiple sclerosis drugsservices market is more probable in the developing countries including India and China as availability of resources, labor and many other at cheaper cost.

Key Benefits for multiple sclerosis drugs Market Reports –

Global multiple sclerosis drugs market report covers in depth historical and forecast analysis. Global multiple sclerosis drugs market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level. Global multiple sclerosis drugs market report helps to identify opportunities in market place. Global multiple sclerosis drugs market report covers extensive analysis of emerging trends and competitive landscape.

Multiple Sclerosis DrugsMarket Segmentation –

Multiple Sclerosis DrugsMarket: by Drug Class

Immune modulator Immune suppressant Interferon Others

Multiple Sclerosis Drugs Market: by Route of Administration

Oral Injection Intravenous Infused Others

Multiple Sclerosis Drugs Market: by Distribution Channel

Hospital pharmacy Retail pharmacy Online stores

Multiple Sclerosis DrugsMarket: by Regional & Country Analysis

North America S. Mexico Canada Europe UK France Germany Italy Asia Pacific China Japan India Southeast Asia South America Brazil, Argentina Columbia The Middle East and Africa GCC Africa Rest of Middle East and Africa

Table of Content

1. Chapter – Report Methodology
1.1. Research Process 
1.2. Primary Research 
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model 
1.7. USP’s of Report 
1.8. Report Description 

2. Chapter – Global Multiple Sclerosis Drugs Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary 
2.3. Global Multiple Sclerosis Drugs Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7.  Multiple Sclerosis Drugs Market: Trends
2.8. Porter’s Five Forces Analysis
2.9. Market Attractiveness Analysis 

3. Chapter – Global Multiple Sclerosis Drugs Market Overview: Quantitative Analysis

4. Chapter – Global Multiple Sclerosis Drugs Market Analysis: Segmentation By Type

5. Chapter – Global Multiple Sclerosis Drugs Market Analysis: Segmentation By Application

Full Research Report @

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or

mail us at








Other Related Report:

This content has been published by Brandessence Market Research and Consulting Pvt ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 28-Aug-2020